A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies

Molecular Therapy

Volumn 11, Issue 3, 2005, Pages 348-362

  Gabril, Manal Y ^a   Duan, Wenming ^a   Wu, Guojun ^a   Moussa, Madeleine ^a   Izawa, Jonathan I ^a   Panchal, Chandra J ^b   Sakai, Hideki ^c   Xuan, Jim W ^a,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

CDNA microarray; Knockout (in) mouse; Mouse cancer modeling; Neuroendocrine carcinoma; Preclinical trials; Prostate cancer; PSP94 ( microseminoprotein); Tumorigenesis and progression

Indexed keywords

BETA MICROSEMINOPROTEIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENTARY DNA; MASPIN;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER MODEL; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE COURSE; DNA MICROARRAY; GENE IDENTIFICATION; GENE MUTATION; HISTOPATHOLOGY; IMMUNE RESPONSE GENE; MALE; MOUSE; NONHUMAN; PROSTATE ADENOCARCINOMA; SCORING SYSTEM; TRANSGENIC MOUSE; TUMOR GROWTH; UPREGULATION;

ADENOCARCINOMA; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS;

MUS MUSCULUS; RODENTIA;

EID: 14044265765     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.12.005     Document Type: Article

References (49)

1. J.T. Isaacs Development and characteristics of the available animal model systems for the study of prostatic cancer In: D.S. Coffey N. Bruchovsky Jr. W.A. Gardner M.I. Resnick J.P. Karr Current (Eds.) Concepts and Approaches to the Study of Prostate Cancer Vol. 239 1987 A. R. Liss New York 513-576
2. C. Abate-Shen M.M. Shen Mouse models of prostate carcinogenesis Trends Genet. 18 2002 S1-S5
3. W.J. Huss L.A. Maddison N.M. Greenberg Autochthonous mouse models for prostate cancer: Past, present and future Semin. Cancer Biol. 11 2001 245-260
4. R.J. Matusik et al. Transgenic mouse models of prostate cancer In: M. Matuk C.W. Brown T.R. Kumar (Eds.) Contemporary Endocrinology: Transgenics in Endocrinology 2001 Humana Press Totowa, NJ 401-425
5. J.E. Green et al. Workgroup 3: Transgenic and reconstitution models of prostate cancer Prostate 36 1998 59-63
6. S.F. Winter A.B. Cooper N.M. Greenberg Models of metastatic prostate cancer: A transgenic perspective Prostate Cancer Prostatic Dis. 6 2003 204-211
7. J.J. Killion R. Radinsky I.J. Fidler Orthotopic models are necessary to predict therapy of transplantable tumors in mice Cancer Metastasis Rev. 17 1998 279-284
8. N.M. Greenberg et al. Prostate cancer in a transgenic mouse Proc. Natl. Acad. Sci. USA 92 1995 3439-3443
9. N. Masumori et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential Cancer Res. 61 2001 2239-2249
10. I.G. Maroulakou M. Anver L. Garrett J.E. Green Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene Proc. Natl. Acad. Sci. USA 91 1994 11236-11240
11. E.M. Garabedian P.A. Humphrey J.I. Gordon A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells Proc. Natl. Acad. Sci. USA 62 1998 227-237
12. C. Perez-Stable N.H. Altman P.P. Mehta L.J. Deftos B.A. Roos Prostate cancer progression, metastasis, and gene expression in transgenic mice Cancer Res. 57 1997 900-906
13. K. Ellwood-Yen et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors Cancer Cell 4 2003 223-238
14. J. DiGiovanni et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice Proc. Natl. Acad. Sci. USA 97 2000 3455-3460
15. S.B. Shappell et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee Cancer Res. 64 2004 2270-2305
16. A. Di Cristofano M. De Acetis A. Koff C. Cordon-Cardo P.P. Pandolfi Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse Nat. Genet. 27 2001 222-224
17. Y. Wang et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue Cancer Res. 60 2000 6008-6017
18. N. Schreiber-Agus et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth Nature 393 1998 483-487
19. K. Podsypanina et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems Proc. Natl. Acad. Sci. USA 96 1999 1563-1568
20. S. Wang et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 4 2003 209-221
21. L.C. Trotman et al. Pten dose dictates cancer progression in the prostate PLoS Biol. 1 2003 E59
22. N. Miyamoto M. Yoshida S. Kuratani I. Matsuo S. Aizawa Defects of urogenital development in mice lacking Emx2 Development 124 1997 1653-1664
23. M.J. Kim et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis Cancer Res. 62 2002 2999-3004
24. C. Abate-Shen et al. Nkx3.1: Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases Cancer Res. 63 2003 3886-3890
25. M.J. Kim et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis Proc. Natl. Acad. Sci. USA 99 2002 2884-2889
26. M. Hara H. Kimura Two prostate-specific antigens, γ-seminoprotein and β-microseminoprotein J. Lab. Clin. Med. 113 1989 541-548
27. P.-A. Abrahamsson H. Lilja S. Falkmer L.B. Wadstrom Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands Prostate 12 1988 39-46
28. H. Hyakutake et al. β-Microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma Prostate 22 1993 347-355
29. J.W. Xuan et al. cDNA, genomic cloning and gene expression analysis of mouse PSP94 (prostate secretory protein of 94 amino acids) DNA Cell Biol. 18 1999 11-26
30. Y. Imasato et al. Rodent PSP94 gene expression is more specific to the dorsolateral prostate and less sensitive to androgen ablation than probasin Endocrinology 142 2001 2138-2146
31. M.Y. Gabril et al. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model Gene Ther. 9 2002 1589-1599
32. C. Lazure M. Villemure D. Gauthier R.J. Naude M. Mbikay Characterization of ostrich (Struthio camelus) beta-microseminoprotein (MSP): identification of homologous sequences in EST databases and analysis of their evolution during speciation Protein Sci. 10 2001 2207-2218
33. W.M. Duan et al. Knock-in of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate (KIMAP) model demonstrates advantageous features over the transgenic model Oncogene 2004 (in press)
34. N. Deshmumukh C.S. Foster Grading prostate cancer In: C.S. Foster D.G. Bostwick (Eds.) Pathology of the Prostate Cancer 1998 Saunders Philadelphia 191-227
35. D.G. Bostwick Neoplasms of the prostate In: D.G. Bostwick J.N. Eble (Eds.) Urologic Surgical Pathology 1997 Mosby St. Louis 343-421
36. D.R. Rhodes M.G. Sanda A.P. Otte A.M. Chinnaiyan M.A. Rubin Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer J. Natl. Cancer Inst. 95 2003 661-668
37. S.M. Dhanasekaran et al. Delineation of prognostic biomarkers in prostate cancer Nature 412 2001 822-826
38. B.W. Futscher et al. Role for DNA methylation in the control of cell type specific maspin expression Nat. Genet. 31 2002 175-179
39. M.L. Cher et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis Proc. Natl. Acad. Sci. USA 100 2003 7847-7852
40. K. Kas et al. ESE-3, a novel member of an epithelium-specific ets transcription factor subfamily, demonstrates different target gene specificity from ESE-1 J. Biol. Chem. 275 2000 2986-2998
41. P. Oettgen et al. Characterization of ESE-2, a novel ESE-1-related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes J. Biol. Chem. 274 1999 29439-29452
42. P.J. Kaplan-Lefko et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model Prostate 55 2003 219-237
43. E. Janssen M. Zhu W. Zhang S. Koonpaew W. Zhang LAB: A new membrane-associated adaptor molecule in B cell activation Nat. Immunol. 4 2003 117-123
44. C.W. Chiu M. Dalton M. Ishiai T. Kurosaki A.C. Chan BLNK: Molecular scaffolding through 'cis'-mediated organization of signaling proteins EMBO J. 21 2002 6461-6472
45. A.I. Evangelou S.F. Winter W.J. Huss R.A. Bok N.M. Greenberg Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype J. Cell Biochem. 91 2004 671-683
46. R. Etzioni et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends J. Natl. Cancer Inst. 94 2002 981-990
47. J.A. Magee et al. Expression profiling reveals hepsin overexpression in prostate cancer Cancer Res. 61 2001 5692-5696
48. Y. Imasato et al. PSP94 expression after androgen deprivation therapy: A comparative study with prostate specific antigen in benign prostate and prostate cancer J. Urol. 164 2000 1819-1824
49. J.R. Reeves et al. Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids Biochem. J. 385 2004 105-114